Modeling opportunities in comparative oncology for drug development

Area of Science:

• Oncology
• Comparative Medicine
• Drug Development

Background:

• Developing novel cancer drugs requires robust preclinical models to predict clinical efficacy and safety.
• Current preclinical models, including in vitro and mouse models, have limitations in replicating human cancer complexity.
• There is a growing need for advanced preclinical models in cancer drug discovery.

Purpose of the Study:

• To evaluate the utility of pet dogs with naturally occurring tumors as a preclinical model for cancer drug development.
• To explore how canine cancer models can address limitations of traditional in vitro and mouse models.
• To determine if canine models provide unique insights for advancing novel cancer therapies.

Main Methods:

• Utilizing pet dogs with spontaneous tumors as a model system for preclinical cancer drug assessment.
• Comparing the biological relevance and data obtained from canine models to conventional in vitro and mouse models.
• Integrating canine cancer studies into the drug development pipeline.

Main Results:

• Canine cancer models share fundamental biological features with human cancers, offering a more relevant system.
• Studies in dogs can answer critical questions about drug activity and safety not addressed by other models.
• This approach provides valuable data to inform the progression of cancer drugs to clinical trials.

Conclusions:

• Pet dogs with naturally occurring tumors represent a promising preclinical model for cancer drug development.
• Integrating canine models can enhance the predictive value of preclinical data for human cancer patients.
• Canine cancer studies offer a unique opportunity to improve the success rate of novel cancer drug approvals.